PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.
Saxena M, Marron TU, Kodysh J, Finnigan JP Jr, Onkar S, Kaminska A, Tuballes K, Guo R, Sabado RL, Meseck M, O'Donnell TJ, Sebra RP, Parekh S, Galsky MD, Blasquez A, Gimenez G, Bicak M, Cimen Bozkus C, Delbeau-Zagelbaum D, Rodriguez D, Acuna-Villaorduna A, Misiukiewicz KJ, Posner MR, Miles BA, Irie HY, Tiersten A, Doroshow DB, Wolf A, Mandeli J, Brody R, Salazar AM, Gnjatic S, Hammerbacher J, Schadt E, Friedlander P, Rubinsteyn A, Bhardwaj N.
Saxena M, et al. Among authors: blasquez a.
Cancer Discov. 2025 May 2;15(5):930-947. doi: 10.1158/2159-8290.CD-24-0934.
Cancer Discov. 2025.
PMID: 40094414
Clinical Trial.